Advertisement

Grenzbereiche der Dosierung von Mesalazin

  • M. Gök
  • L. Oelschlegel
Conference paper
Part of the Gastroenterologie Update book series (GASTROUPDATE, volume 2001)

Zusammenfassung

In den vergangenen Dekaden konnten Fortschritte bei der medikamentösen Behandlung der chronisch entzündlichen Darmerkrankungen (CED) erreicht werden.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ardizzone S, Porro GB (1998) A practical guide to the management of distal ulcerative colitis. Drugs 55: 519–542PubMedCrossRefGoogle Scholar
  2. Azad Khan AK, Piris J, Truelove SC (1977) An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 2:892–895Google Scholar
  3. Camma C, Giunta M, Rosselli M, Cottone M (1997) Mesalamine in the maintainance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 113:1465–1473PubMedCrossRefGoogle Scholar
  4. Campieri M, Lanfranchi GA, Bertoni F et al. (1984) A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion 29:204–208PubMedCrossRefGoogle Scholar
  5. Caprilli R, Andreoli A, Capruso L et al. (1994) Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn’s disease. Aliment Pharmacol Ther 8:35–43PubMedCrossRefGoogle Scholar
  6. Christensen LA (1992) Release profiles and local/systemic availabilities of five oral 5- ASA-containing preparations. In: Rasmussen SN (ed) Pentasa in ulcerative colitis and Crohn’s disease. Symposium proceedings, Helsingor, Denmark 1991. Adis International, ChesterGoogle Scholar
  7. Colombel J-F, Lémann M, Cassagnou M et al. (1999) A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Am J Gastroenterol 94: 674–678PubMedCrossRefGoogle Scholar
  8. De Franchis R, Vecchi M, Carpinelli 1, Meucci G, Torgana G (1993) Comparison of the efficacy and safety of sulfasalazine and mesalazine in the maintenance of treatment of ulcerative colitis: a meta-analysis. Eur J Gastroenterol Hepatol 5:505–510Google Scholar
  9. Ewe K, Herfarth C, Malchow H, Jesdinsky HJ (1989) Post-operative recurrence of Crohn’s disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 42:224–232PubMedCrossRefGoogle Scholar
  10. Feuerle GE, Theuer D, Velasco S, Barry BA, Wordehoff D, Sommer A et al. (1989) Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomized double-blind trial. Gut 30:1354–1361CrossRefGoogle Scholar
  11. Fockens P, Mulder CJJ, Tytgat GNJ, Blok P, Ferweda J, and the Dutch Pentasa Study Group (1995) Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol 7:1025–1030PubMedCrossRefGoogle Scholar
  12. Frieri G, Pimpo MT, Andreoli A et al. (1999) Prevention of post-operative recurrence of Crohn’s disease requires adequate mucosal concentration of mesalazine. Aliment Pharmacol Ther 13: 577–582PubMedCrossRefGoogle Scholar
  13. Frieri G, Pimpo MT, Palumbo G, Tonelli F, Annese V et al. of the GISC (2000) Anastomotic configuration and mucosal 5-aminosalicylic acid (5-asa) concentrations in patients with Crohn’s disease: a GISC study. Am J Gastroenterol 95(6):1486–1490PubMedCrossRefGoogle Scholar
  14. Gandolfo J, Farthing F, Powers G et al. (1987) 4-aminosalicylic acid retention enemas in treatment of distal colitis. Dig Dis Sci 32(7): 700–704PubMedCrossRefGoogle Scholar
  15. Ginsberg AL, Beck LS, McIntosh TM, Nochomovitz LE (1988) Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas: a double-blind, placebo-controlled trial. Ann Intern Med 108:195–199PubMedGoogle Scholar
  16. Hanauer S, Schwartz J, Robinson M, Roufail W, Arora S, Cello J, Safdi M, and the Pentasa Study Group (1993) Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 88(8): 1188–1197PubMedGoogle Scholar
  17. Hanauer SB (1989) 5-ASA enema therapy. Neth J Med 35: S11–S20PubMedGoogle Scholar
  18. Hanauer SB (1996) Inflammatory bowel disease. New Engl J Med 334: 841–848PubMedCrossRefGoogle Scholar
  19. Hanauer SB, Schwartz J, Roufail W, Robinson M, Cello J, Safdi M et al. (1989) Doseranging study of oral mesalamine capsule (PENTASA) for active ulcerative colitis. Gastroenterology (Abstract) 96:A195Google Scholar
  20. Hetzel DJ, Shearman DJC, Bochner F, Imhoff DM, Gibson GE, Fitch RJ et al. (1986) Azodisalicylate (olsalazine) in the treatment of active ulcerative colitis. A placebo-controlled clinical trial and assessment of drug disposition. J Gastroent Hepatol 1: 257–266CrossRefGoogle Scholar
  21. Jarnerot G (1994) New salicylates as maintenance treatment in ulcerative colitis. Gut 35:1155–1158PubMedCrossRefGoogle Scholar
  22. Klotz U (2000) The role of aminosalicylates at the beginning of the new millenium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol 56: 353–362PubMedCrossRefGoogle Scholar
  23. Lochs H, Mayer M, Fleig WE et al. (2000) Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine. Gastroenterology 118: 264–273PubMedCrossRefGoogle Scholar
  24. Mahida YR, Yewell DP (1990) Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn’s disease. Digestion 45: 88–92PubMedCrossRefGoogle Scholar
  25. Marshall JK, Irvine EJ (1995a) Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 40: 775–781CrossRefGoogle Scholar
  26. Marshall JK, Irvine EJ (1995b) Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 9: 293–300CrossRefGoogle Scholar
  27. Messori A, Brignola C, Trallori G et al. (1994) Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: a meta-analysis. Am J Gastroenterol 89:692–698PubMedGoogle Scholar
  28. Messori A, Rampazzo R (1993) Meta-analysis on the maintainance of remission in Crohn’s disease. J Clin Gastroenterol 17:178–180PubMedCrossRefGoogle Scholar
  29. Mulder CJJ, van den Hazel SJ (1998) Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease. Mediators of Inflammation 7:135–136PubMedCrossRefGoogle Scholar
  30. Munakata _ et al. (1995) _ J Gastroenterol 30 (Suppl VIII): 108–111PubMedGoogle Scholar
  31. Powell-Tuck J, Parkins RA (1984) Controlled comparison of enemas containing 1 g and 2 g 5-Aminosalicylic acid in patients with ulcerative proctosigmoiditis. Gut 25 (Abstract):A11423Google Scholar
  32. Prakash A, Markham A (1999) Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn’s disease. Drugs 57: 383–408PubMedCrossRefGoogle Scholar
  33. Rasmussen SN, Lauritsen K, Tage-Jensen U (1987) 5-Aminosalicylic acid in the treatment of Crohn’s disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 22: 877–883PubMedCrossRefGoogle Scholar
  34. Riley SA (1998) What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut 42:761–763PubMedCrossRefGoogle Scholar
  35. Robinson M, Girnick G, Balant L, Das K, Turkin D (1988) Olsalazine in the treatment of mild to moderate ulcerative colitis. Gastroenterology (Abstract) 84: A381Google Scholar
  36. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, Koval G et al. (1997) A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92(10): 1867–1871PubMedGoogle Scholar
  37. Salomon P, Kornbluth A, Aisenberg J, Janowitz HD (1992) How effective are current drugs for Crohn’s disease? A meta-analysis. J Clin Gastroenterol 14:211–215PubMedCrossRefGoogle Scholar
  38. Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317:1625–1629PubMedCrossRefGoogle Scholar
  39. Selby WS, Bennett MK, Jewell DP (1984) Topical treatment of distal ulcerative colitis with 4-aminosalicylic acid enemas. Digestion 29:231PubMedCrossRefGoogle Scholar
  40. Singleton J (1994) Second trial of mesalamine therapy in the treatment of active Crohn’s disease. Gastroenterology 107: 632–633PubMedGoogle Scholar
  41. Singleton JW, Hanauer SB, Gitnick GL et al. (1993) Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Gastroenterology 104: 1293–1301PubMedGoogle Scholar
  42. Sninsky CA, Cort DH, Shanaban F, Powers BJ, Sessions JT, Pruitt RE et al. (1991) Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 115:350–355PubMedGoogle Scholar
  43. Steinhart AH, Hemphill D, Greenberg GR (1994) Sulfasalazine and mesalazine for the maintainance therapy of Crohn’s disease: a meta-analysis. Am J Gastroenterol 89: 2116–2214PubMedGoogle Scholar
  44. Sutherland LR (1999) Aminosalicylates in the treatment of ulcerative colitis and Crohn’s disease. In: Rutgeerts P, Colombel J-F, Hanauer SB, Schölmerich J, Tytgat GMH, van Gossum A (eds) Advances in inflammatory bowel diseases. Kluwer Academic Press, Dordrecht, pp 201–209Google Scholar
  45. Sutherland LR (2000) Mesalamine for the prevention of postoperative recurrence: is nearly there the same as being there? Gastroenterology 118: 436–438PubMedCrossRefGoogle Scholar
  46. Sutherland LR, Robinson M, Onstad G, Peppercorn M, Greenberger N, Goodman M et al. (1990) A double-blind, placebo-controlled, multi-centre study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis. Can J Gastroenterol 4: 463–467Google Scholar
  47. Sutherland LR, Roth DE, Beck PL (1997) Alternatives to sulfasalazine: a meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis 3: 65–78CrossRefGoogle Scholar
  48. Sutherland LR, Shaffer EA (1993) Sulfasalazine revisited: a meta-analysis of 5-amino-salicylic acid in the treatment of ulcerative colitis. Ann Int Med 118: 540–549PubMedGoogle Scholar
  49. Svartz N (1942) Salazopyrin, a new sulfanilamide preparation. Acta Medica Scandinavia 110:557–590Google Scholar
  50. Tremain WJ, Schroeder KW, Harrison JM, Zinsmeister AR (1994) A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preperation, Asacol, in the treatment of symptomatic Crohn’s colitis and ileocolitis. J Clin Gastoenterol 19:278–282CrossRefGoogle Scholar
  51. Tromm A, Griga T, May B, (1999) Oral mesalazine for the treatment of Crohn’s disease: clinical efficacy with respect to pharmacokinetic properties. Hepatogastroenterology 46:3124–3135PubMedGoogle Scholar
  52. Wilding IR, Kenyon CJ, Hooper G (2000) Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa®) dosed as either tablets or sachet. Aliment Pharmacol Ther 14:163–169PubMedCrossRefGoogle Scholar
  53. Wright JP, Jewell DP, Modigliani R, Malchow H for the International Organisation for the Study of Inflammatory Bowel Disease (IOIBD) (1995) A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn’s disease. Inflamm Bowel Dis 1:214–216Google Scholar
  54. Zinberg J, Molinas S, Das KM (1990) Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 85:562–566PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  • M. Gök
  • L. Oelschlegel

There are no affiliations available

Personalised recommendations